公开(公告)号：EP3865472A1

公开(公告)日：2021-08-18

申请号：EP20212296.6

申请日：2016-06-13

申请人： ATXA Therapeutics Limited

发明人： KINSELLA, B. Therese ,  REID, Helen

IPC分类号： C07C311/58 ,  A61K31/64 ,  A61P3/10 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/08 ,  A61P13/12 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

摘要： The invention relates to novel chemical entities that act as thromboxane (TX) A 2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G 2 /PGH 2 , 20-hydroxyeicosatetraenoic acid (20-HETE) and the free -radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F 2α ), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.

公开(公告)号：EP4178547A1

公开(公告)日：2023-05-17

申请号：EP21748790.9

申请日：2021-07-06

申请人： ATXA Therapeutics Limited

发明人： KINSELLA, B. Therese ,  REID, Helen ,  MULVANEY, Eamon

IPC分类号： A61K9/16 ,  A61K9/48 ,  A61K31/64 ,  A61P9/00 ,  A61P11/00 ,  A61P17/00 ,  A61P35/00